Citi Comments Earlier on Acadia Pharmaceuticals (ACAD): 'removes an overhang for some investors'
Tweet Send to a Friend
Citi analyst David Hoang reiterated a Buy rating and $38.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments "ACAD ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
